Navigation Links
Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Date:11/11/2008

KANSAS CITY, Mo., Nov. 11 /PRNewswire/ -- An investor group in Trinity Biotech plc (Nasdaq: TRIB), an Irish based developer and manufacturer of diagnostic products whose shares are traded in the form of American Depository Receipts ("ADRs") on NASDAQ, has initiated a campaign for conversion of company ADRs to ordinary shares to bring about a special meeting of shareholders to consider a change in the board.

This campaign follows the recent refusal by Trinity Biotech directors to honor an earlier request by a group of ADR holders for the calling of a special meeting of shareholders to consider the removal and replacement of the company's current directors. The directors' rejection of the request was based on their determination that ADRs have fewer rights under Irish law than the ordinary shares into which they may be converted. The directors also refused to take alternative steps proposed by the requesting group to convene the meeting.

Commenting on the campaign, Tom Reidy stated, "The directors' blatant disregard for our basic rights as owners of the company has only heightened our resolve to impose accountability on company management. We are calling on all ADR holders who believe that a board change is in order to join with us in converting ADRs to ordinary shares. While none of us should be forced to take this unnecessary step, we believe this is the only way we can protect our investment."

Important Next Steps: ADR holders who would like assistance in converting their ADRs should contact Mr. Reidy at tjreidy3@hotmail.com or (816) 260-8476.


'/>"/>
SOURCE KC Investor Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
2. Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
3. Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008
4. Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
5. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
6. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
7. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  Aethlon Medical, ... following note authored by its Chairman and CEO, ... at the Munich Security Conference last Saturday, Bill ... virus could kill more people than nuclear weapons. Mr. ... U.S. and U.K. intelligence agencies, that scientific terrorists have ...
(Date:2/24/2017)... HONG KONG, Feb. 24, 2017 China Cord Blood ... "Company"), China,s leading provider of cord blood collection, laboratory ... services, today announced its unaudited financial results for the ... 2017 ended December 31, 2016. Third Quarter ... the third quarter of fiscal 2017 increased by 18.6% ...
(Date:2/24/2017)... Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), the ... laboratory and production customers, today reported its financial results for ... Highlights: 4Q16 record quarterly ... 1.0% on an organic basis. ... an organic basis, while the Americas net sales increased 2.5%, ...
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
Breaking Biology Technology:
(Date:1/30/2017)... SAN FRANCISCO , Jan. 30, 2017   ... of the fastest growing genetic information companies, today announced ... 2016 financial results and provide 2017 guidance on Monday, ... a conference call that day at 4:45 p.m. Eastern ... call, Invitae,s management team will briefly review financial results, ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile market ... prices have dropped dramatically. The quarterly average price of ... to $276 in Q4 2016.  There are now 120 ... of $116, up from just 28 a year ago ... According to Maxine Most , Acuity Market Intelligence ...
Breaking Biology News(10 mins):